Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data validation
1.4 Forecast parameters
1.5 Data sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360-degree synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of hormonal disorders
3.2.1.2 Rising awareness about women's health
3.2.1.3 Favorable government initiatives and healthcare policies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Formulation, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Natural
5.3 Synthetic
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Injectable
6.3 Oral
6.4 Transdermal
6.5 Other routes of administration
Chapter 7 Market Estimates and Forecast, By Application, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Menopause
7.3 Contraception
7.4 Dysfunctional uterine bleeding
7.5 Hyperplastic precursor lesions
7.6 Endometrial cancer
7.7 Other applications
Chapter 8 Market Estimates and Forecast, By Drug Type, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Branded
8.3 Generic
Chapter 9 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Mn)
9.1 Prescription
9.2 OTC
Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 Hospital pharmacy
10.3 Retail pharmacy
10.4 Online pharmacy
Chapter 11 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
11.1 Key trends
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Spain
11.3.5 Italy
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 Australia
11.4.5 Rest of Asia Pacific
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest of Latin America
11.6 Middle East and Africa
11.6.1 South Africa
11.6.2 Saudi Arabia
11.6.3 Rest of Middle East and Africa
Chapter 12 Company Profiles
12.1 Alkem Laboratories Ltd.
12.2 Aquatic Group
12.3 Bionpharma Inc.
12.4 Cadila Pharmaceuticals
12.5 Cipla Inc.
12.6 Estrellas Life Sciences Private Limited.
12.7 Eli Lily & Company
12.8 Glenmark Pharmaceuticals Ltd.
12.9 Insud Pharma S.L.U.
12.10 Lupin
12.11 Novo Nordisk A/S
12.12 Teva Pharmaceutical Industries Ltd
